Cyrcadia Health Takes Home Gold 2016 Edison Award for Top Health and Wellness Wearable

Share Article

Ground Breaking Wearable iTBra™ Technology Holds Promise for Early Breast Cancer Detection

Not only did Cyrcadia win, but the company beat hundreds of other innovators and dozens in this category to achieve this designation

Cyrcadia, Inc. was recently awarded the gold level citation for Health and Wellness, Wearable and Sensors category from the prestigious Edison Organization presented last week at the annual gala in New York. The company’s breakthrough technology is designed to enable early breast cancer detection through use of a wearable device, the iTBra.™ The technology measures specific circadian biomarkers, which can be early indicators of breast cancer cell infusion.

“Not only did Cyrcadia win, but the company beat hundreds of other innovators and dozens in this category to achieve this designation,” said Jason Starbird, CEO, Aebli Group/ Edison. “One in eight women in the U.S. are diagnosed with breast cancer annually and approximately 500,000 women die worldwide from the disease each year, many due to lack of early detection. The Cyrcadia technology may become a substantial game changer.”

Cyrcadia’s wearable, smart phone-enabled iTBra technology, uses a comfortable data collection device placed under a bra to collect from two to twelve hours of breast cell data (dynamic cell chaos). Circadian rhythm-based temperature variances of cell cycles are then measured through a Cyrcadia-patented process to identify abnormalities at the earliest stages of cellular change over time.

The results collected from the technology are transferred through a smart device to a global cancer library, where advanced analytical analysis occurs. The results then are communicated back to the patient and physician.

“We are honored to be receiving this highly regarded award,” said Rob Royea, president of Cyrcadia. “There are numerous and exciting technologies being developed in the healthcare field, which makes the selection of Cyrcadia as the gold winner even more significant to us. Most importantly, the final goal is to deliver earlier cancer detection to all women in order to save more lives.”

Clinical trials are currently underway at El Camino Hospital in Mountain View, California and The Ohio State University in Columbus, Ohio. These studies are supported financially by the Canary Foundation, the only foundation in the world which, over the past 10 years, has focused solely on early cancer detection. Cyrcadia and the Canary Foundation will be collaborating on early biomarker identification for breast cancer. The ability to correlate the Cyrcadia findings with those biomarkers, which are early indicators of breast cancer cell infusion, are invaluable and could lead to earlier therapy intervention in the progression of breast cancer.

About Cyrcadia, Inc.

Cyrcadia, Inc., also known as Cyrcadia Health, was founded as First Warning Systems in 2008, is based in Reno, Nev. The company’s product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia is underway in a final, limited clinical trial and a 510k device classification to validate the product. Cyrcadia technology is exclusively licensed for development, manufacturing and marketing worldwide from Lifeline Biotechnologies, Inc (OTC Market: LLBO). Cyrcadia is preparing to apply for FDA Clearance and a Euro CE Mark to market in the European Union and Asia Pacific markets, with anticipation of launching its technology to market in 2017. Furthermore, Cisco Systems, Inc. has financially supported the making of a documentary by Ironbound Films about the evolution of Cyrcadia technology, called “Detected Movie” to be released. Please visit http://www.DetectedMovie.com and Cyrcadia Health at http://www.cyrcadiahealth.com.

Per Federal FDAAA 801 guidelines, Cyrcadia will release information on trial location additions, as well as clinical trial data only at time of trial completion or FDA clearance for disclosure.

About the Edison Awards

The Edison Awards is a program conducted by Edison Universe, a non-profit, 501(c)(3) organ¬ization dedicated to fostering future innovators. The Awards have been recognizing and honor¬ing the best in innovations and innovators since 1987. They honor game-changing innovations that are at the forefront of new product and service development, marketing and human-centered design, and are one of the highest accolades a company can receive in the name of successful innovation. For more information visit http://www.edisonawards.com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laurie Hallwyler
ckj Communications
+1 650-248-9081
Email >

Laurie Hallwyler
Visit website